Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Conference Call - Hemispherx Responds to

|Includes: AIM ImmunoTech Inc. (AIM)

StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), which hopes its drug, Ampligen will be approved to treat Chronic Fatigue Syndrome (CFS).

At approximately 3:30pm EST, 5/29/09, StocksHaven Investments began the call conference scheduled with Chairman & CEO of Hemispherx BioPharma Inc., Dr. William Carter. The basis interview was with regards to’s Adam Feuerstein’s recent article, “Hemispherx’s CFS Drug Is a Long Shot“. The interview was concluded as of 4:00pm EST, 5/29/09. Many issues and concerns of private individual investors were raised and answered in a both informative and intellectual manner by Dr. Carter.

For the full exclusive interview visit http://www.StocksHaven...

Disclosure: Long-Term Position